Medications That Cause Anemia
Numerous medications can cause anemia through multiple mechanisms, with chemotherapy agents, antibiotics (especially cephalosporins), proton pump inhibitors, oral anticoagulants, and certain immunosuppressants being the most clinically significant culprits.
Mechanisms and Drug Categories
Chemotherapy-Induced Anemia
Myelosuppressive chemotherapy is a leading cause of drug-induced anemia, directly suppressing bone marrow production of red blood cells 1. This represents the most common iatrogenic cause in oncology patients and requires specific monitoring protocols.
Immune-Mediated Hemolytic Anemia
Recent large-scale pharmacovigilance data identified over 112 drugs associated with drug-induced immune hemolytic anemia (DIIHA) 2. The most significant include:
- Antibiotics: Second and third-generation cephalosporins are particularly problematic 3, with newer evidence confirming strong associations 2
- Antifungal agents 2
- Methyldopa: Historically one of the first recognized causes of autoimmune hemolytic anemia 3
- Diclofenac and other NSAIDs: Ibuprofen specifically shows association with immune hemolytic anemia 2
- Fludarabine: Frequently associated with hemolytic anemia in chronic lymphocytic leukemia patients 3
Iron Deficiency Anemia
A 2024 case-control study demonstrated independent associations between IDA development and:
- Proton pump inhibitors (OR 3.29,95% CI: 2.47-4.41) - the strongest association, likely through impaired iron absorption 4
- Oral anticoagulants (OR 2.04,95% CI: 1.29-3.24) - primarily through occult bleeding from hemorrhagic lesions 4
Bone Marrow Suppression
Beyond chemotherapy, several drugs cause aplastic anemia or suppress RBC production 5:
Megaloblastic Anemia
Drugs interfering with folate metabolism 1, 5:
- Hydroxyurea 1
- Diphenytoin and other anticonvulsants 1, 6
- Methotrexate and other dihydrofolate reductase inhibitors 6
Sideroblastic Anemia
Less common but important 1, 6:
- Antituberculosis medications 6
Other Mechanisms
- Furosemide: Associated with immune hemolytic anemia 2
- Iomeprol (contrast agent): Linked to hemolytic anemia 2
- Erythropoiesis-stimulating agents (ESAs): Paradoxically can cause pure red cell aplasia through antibody formation 1
Clinical Pitfalls and Monitoring
Critical caveat: The association between PPIs and iron deficiency anemia is particularly insidious because these medications are widely prescribed and the anemia develops insidiously over time 4. Consider iron supplementation or PPI discontinuation in at-risk patients.
ESA-related concerns: Any sudden loss of response to ESAs with severe anemia and low reticulocyte count warrants immediate evaluation for antibody-mediated pure red cell aplasia 1. ESAs should be permanently discontinued if confirmed, and patients should not be switched to alternative ESA products due to antibody cross-reactivity.
Polypharmacy risk: The problem intensifies in aging populations with multiple comorbidities taking numerous medications simultaneously 5. Maintain high clinical suspicion when evaluating anemia in patients on multiple drugs.
Diagnostic Approach
When drug-induced anemia is suspected, evaluate:
- MCV classification: Microcytic (iron deficiency from PPIs/anticoagulants), normocytic (hemolysis, bone marrow suppression), or macrocytic (folate antagonists) 1
- Reticulocyte index: Low suggests production defect (chemotherapy, aplastic anemia); high suggests hemolysis or bleeding 1
- Direct Coombs test: Positive in immune-mediated hemolytic anemia 1
- Medication timing: Temporal relationship between drug initiation and anemia onset
- Iron studies, ferritin, TIBC: For suspected iron deficiency 1
The strength of evidence varies considerably, with the most robust data coming from the 2024 nationwide cohort study on DIIHA 2 and the 2024 case-control study on iron deficiency 4, while guideline recommendations for chemotherapy-induced anemia remain well-established 1.